The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
复制标题
DOI：
10.1016/j.hemonc.2013.09.005
复制
发表时间：
2014-03-01
期刊：
影响因子：
--
通讯作者：
Dermime, Said
中科院分区：
文献类型：
--
作者：
Afreen, Sehar;Dermime, Said
癌症中 B7-H1（也称为 PDL-1 或 CD 274）分子的过度表达与多种恶性肿瘤的预后较差和抗癌治疗耐药有关。在这篇综述中，我们更新了 B7-H1 分子在实体瘤和血液恶性肿瘤中的表达。我们还描述了该分子抑制/下调对癌细胞的免疫反应的可能机制。最后，我们强调了当前和未来潜在的治疗策略，可以进一步开发以针对该分子。
Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of B7-H1 molecule in solid and hematological malignancies. We also describe the possible mechanisms by which this molecule inhibits/downregulates the immune response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that can be further developed to target this molecule.